<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-530
Date of Submission: 2025-02-10

This report was submitted by a Pharmacist from Graves Group Medical Center concerning patient ANON-PX-4403. The subject is a 30-year-old other with a significant medical history including atrial fibrillation, coronary artery disease, hypertension, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Levothyroxine administered via the Intramuscular route at a dosage of 224mg, initiated on 2024-12-09 for Hypothyroidism with the course ongoing.

On approximately 2025-01-06, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Nausea, Stevens-Johnson syndrome. The Pruritus was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Nausea was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed across and advised image. The current patient status regarding this symptom is 'Fatal'. The Stevens-Johnson syndrome was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 3 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Would account social son benefit. Its fly resource middle view clear billion. Billion century increase.</data>
report_id: ADR-2025-530
report_date: '2025-02-10'
patient_details:
  patient_id: ANON-PX-4403
  gender: Other
  relevant_history:
  - atrial fibrillation
  - coronary artery disease
  - hypertension
  - type 2 diabetes
  age_at_reaction: 30
suspected_drugs:
- drug_name: Levothyroxine
  dosage: 224mg
  route_of_administration: Intramuscular
  start_date: '2024-12-09'
  indication_for_use: Hypothyroidism
adverse_reactions:
- symptom_name: Pruritus
  onset_date: '2025-01-06'
  severity: Severe
  outcome: Recovered
  intervention_required: false
- symptom_name: Nausea
  onset_date: '2025-01-06'
  severity: Mild
  outcome: Fatal
  intervention_required: true
  intervention_details: Prescribed across and advised image.
- symptom_name: Stevens-Johnson syndrome
  onset_date: '2025-01-06'
  severity: Life-threatening
  outcome: Recovering
  intervention_required: false
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Not applicable
  naranjo_score: 3
reporting_facility: Graves Group Medical Center
reporter_type: Pharmacist
notes: Would account social son benefit. Its fly resource middle view clear billion.
  Billion century increase.
